Work

A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials

Year: 2022

Type: article

Source: Leukemia

DOI: 10.1038/s41375-022-01622-0

Authors: Mohammed O. Gbadamosi, Vivek M. Shastri, Abdelrahman H. Elsayed, Rhonda Ries, Oluwaseyi Olabige, Nam H. K. Nguyen, Angelica De Jesus, Yi-Cheng Wang, Alice Dang, Betsy A. Hirsch, Todd A. Alonzo, Alan Gamis, Soheil Meshinchi, Jatinder K. Lamba

Institutions: University of Florida, Fred Hutch Cancer Center, Children's Oncology Group, University of Minnesota, University of Southern California, Children's Mercy Hospital

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, Leukemia and Lymphoma Society, National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, National Cancer Institute

Awards: G1504112592, G151151853, G2901481919, G3209343207, Children's Oncology Group Statistics and Data Center, Impact of genetic variation on response to GO therapy in COG-AML clinical trials, G6234804779, G6696704968, G997771125

OpenAlex ID: W4281734156

FWCI: 1.405

Cites: 28

Cited by: 10

Related to: 10